Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news about their two asthma therapies, Enerzair Breezhaler and Atectura Breezhaler.
Saviuk telling Proactive the company has entered into a Product Listing Agreement with the Alberta Minister of Health, for the listing and public reimbursement of these products. This becomes the First provincial public listing secured for both asthma medications.